AAAAAA
Results:
1-22
|
Results: 22
Authors:
Augenbraun, M
Tarwater, P
Greenblatt, R
Cohen, M
French, A
Gore, ME
Watts, H
Preston-Martin, J
Anastos, K
Citation: M. Augenbraun et al., Opportunistic infection prophylaxis in the Women's Interagency HIV Study (WIHS), J ACQ IMM D, 28(2), 2001, pp. 195-197
Authors:
Jacobson, LP
Gore, ME
Strathdee, SA
Phair, JP
Riddler, S
Detels, R
Citation: Lp. Jacobson et al., Therapy naivete in the era of patent antiretroviral therapy, J CLIN EPID, 54(2), 2001, pp. 149-156
Authors:
Gordon, AN
Fleagle, JT
Guthrie, D
Parkin, DE
Gore, ME
Lacave, AJ
Citation: An. Gordon et al., Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan, J CL ONCOL, 19(14), 2001, pp. 3312-3322
Authors:
Fearfield, LA
Rowe, A
Francis, N
Fisher, C
Gore, ME
Bunker, CB
Citation: La. Fearfield et al., Clinico-pathological features of relapsing very thin melanoma, CLIN EXP D, 26(8), 2001, pp. 686-695
Authors:
Vergote, I
De Brabanter, J
Fyles, A
Bertelsen, K
Einhorn, N
Sevelda, P
Gore, ME
Kaern, J
Verrelst, H
Sjovall, K
Timmerman, D
Vandewalle, J
Van Gramberen, M
Trope, CG
Citation: I. Vergote et al., Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma, LANCET, 357(9251), 2001, pp. 176-182
Authors:
Gibbs, DD
Gore, ME
Citation: Dd. Gibbs et Me. Gore, Pursuit of optimum outcomes in ovarian cancer - Methodological approaches to therapy, DRUGS, 61(8), 2001, pp. 1103-1120
Authors:
Stebbing, J
Benson, C
Eisen, T
Pyle, L
Smalley, K
Bridle, H
Mak, I
Sapunar, F
Ahern, R
Gore, ME
Citation: J. Stebbing et al., The treatment of advanced renal cell cancer with high-dose oral thalidomide, BR J CANC, 85(7), 2001, pp. 953-958
Authors:
Tarwater, PM
Mellors, J
Gore, ME
Margolick, JB
Phair, J
Detels, R
Munoz, A
Citation: Pm. Tarwater et al., Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts, AM J EPIDEM, 154(7), 2001, pp. 675-681
Authors:
Gregory, RK
Hill, ME
Moore, J
A'Hern, RP
Johnston, SRD
Blake, P
Shephard, J
Barton, D
Gore, ME
Citation: Rk. Gregory et al., Combining platinum, paclitaxel and anthracycline in patients with advancedgynaecological malignancy, EUR J CANC, 36(4), 2000, pp. 503-507
Authors:
Piccart, MJ
Du Bois, A
Gore, ME
Neijt, JP
Pecorelli, S
Pujade-Lauraine, E
Citation: Mj. Piccart et al., A new standard of care for treatment of ovarian cancer, EUR J CANC, 36(1), 2000, pp. 10-12
Authors:
Vaughan, MM
Moore, J
Riches, PG
Johnston, SRD
A'Hern, RP
Hill, ME
Eisen, T
Ayliffe, MJ
Thomas, JM
Gore, ME
Citation: Mm. Vaughan et al., GM-CSF with biochemotherapy (cisplatin, DTIC, tamoxifen, IL-2 and interferon-alpha): A phase I trial in melanoma, ANN ONCOL, 11(9), 2000, pp. 1183-1189
Authors:
Palmer, KJ
Harries, M
Gore, ME
Collins, MKL
Citation: Kj. Palmer et al., Interferon-alpha (IFN-alpha) stimulates anti-melanoma cytotoxic T lymphocyte (CTL) generation in mixed lymphocyte tumour cultures (MLTC), CLIN EXP IM, 119(3), 2000, pp. 412-418
Authors:
Allen, MJ
Vaughan, M
Webb, A
Johnston, S
Savage, P
Eisen, T
Bate, S
Moore, J
Ahern, R
Gore, ME
Citation: Mj. Allen et al., Protracted venous infusion 5-fluorouracil in combination with subcutaneousinterleukin-2 and alpha interferon in patients with metastatic renal cell cancer: a phase II study, BR J CANC, 83(8), 2000, pp. 980-985
Authors:
Eisen, T
Boshoff, C
Mak, I
Sapunar, F
Vaughan, MM
Pyle, L
Johnston, SRD
Ahern, R
Smith, IE
Gore, ME
Citation: T. Eisen et al., Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer, BR J CANC, 82(4), 2000, pp. 812-817
Authors:
Tsahalina, E
Woolas, RP
Carter, PG
Chan, F
Gore, ME
Blake, PM
Shepherd, JH
Barton, DPJ
Citation: E. Tsahalina et al., Gastrostomy tubes in patients with recurrent gynaecological cancer and intestinal obstruction, BR J OBST G, 106(9), 1999, pp. 964-968
Authors:
Palmer, K
Moore, J
Everard, M
Harris, JD
Rodgers, S
Rees, RC
Murray, AK
Mascari, R
Kirkwood, J
Riches, PG
Fisher, C
Thomas, JM
Harries, M
Johnston, SRD
Collins, MKL
Gore, ME
Citation: K. Palmer et al., Gene therapy with autologous, interleukin 2-secreting tumor cells in patients with malignant melanoma, HUM GENE TH, 10(8), 1999, pp. 1261-1268
Authors:
Bonnefoi, H
Gore, ME
Citation: H. Bonnefoi et Me. Gore, Optimal cytoreduction in stage IV ovarian carcinoma - In reply, J CL ONCOL, 17(9), 1999, pp. 3004-3004
Authors:
Bonnefoi, H
A'Hern, RP
Fisher, C
Macfarlane, V
Barton, D
Blake, P
Shepherd, JH
Gore, ME
Citation: H. Bonnefoi et al., Natural history of stage IV epithelial ovarian cancer, J CL ONCOL, 17(3), 1999, pp. 767-775
Authors:
Bridgewater, JA
Nelstrop, AE
Rustin, GJS
Gore, ME
McGuire, WP
Hoskins, WJ
Citation: Ja. Bridgewater et al., Comparison of standard and CA-125 response criteria in patients with epithelial ovarian cancer treated with platinum or paclitaxel, J CL ONCOL, 17(2), 1999, pp. 501-508
Authors:
Parry-Jones, N
Gore, ME
Taylor, J
Treleaven, JG
Citation: N. Parry-jones et al., Delayed haemolytic transfusion reaction caused by anti-M antibody in a patient receiving interleukin-2 and interferon for metastatic renal cell cancer, CLIN LAB H, 21(6), 1999, pp. 407-408
Authors:
Gore, ME
Citation: Me. Gore, ICON2 trial, LANCET, 353(9152), 1999, pp. 587-588
Authors:
Mitchell, PL
Al-Nasiri, N
A'Hern, R
Fisher, C
Horwich, A
Pinkerton, CR
Shepherd, JH
Gallagher, C
Slevin, M
Harper, P
Osborne, R
Mansi, J
Oliver, T
Gore, ME
Citation: Pl. Mitchell et al., Treatment of nondysgerminomatous ovarian germ cell tumors - An analysis of69 cases, CANCER, 85(10), 1999, pp. 2232-2244
Risultati:
1-22
|